Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose The quality of anticoagulation is critical for ensuring the benefit of warfarin, but this has been less well studied in Korean ischemic stroke patients with atrial fibrillation (AF). Methods This study retrospectively analyzed the data of patients who had an AF-related ischemic stroke and were treated with long-term warfarin therapy in 16 Korean centers. The quality of warfarin therapy was primarily assessed by the time in therapeutic range [TTR; international normalized ratio (INR), 2.0–3.0] and additionally by the proportion of INR values within the therapeutic range. Results The long-term warfarin-treated cohort comprised 1,230 patients. They were aged 70.1±9.7 years (mean±SD), 42.5% were female, and their CHA2DS2-VASc score was 4.75±1.41. The TTR analysis included 33,941 INR measurements for 27,487 months: per patients, 27.6 (SD, 22.4) INR measurements for 22.4 (SD, 12.9) months. The mean TTR of individual patients was 49.1% (95% confidence interval, 47.9–50.3%), and the TTR quartiles were <34.5, 34.5–49.1, 49.1– 64.5%, and >64.5%. None of the 16 centers achieved a mean TTR of >60%. Of all INR measurements, 44.6% were within the therapeutic range, 41.7% were <2.0, and 13.7% were >3.0. Conclusions In Korean ischemic stroke patients who had AF, the quality of warfarin therapy was low and might be inadequate to effectively prevent recurrent stroke or systemic embolism.
Abstract
Background and Purpose The quality of anticoagulation is critical for ensuring the benefit of warfarin, but this has been less well studied in Korean ischemic stroke patients with atrial fibrillation (AF). Methods This study retrospectively analyzed the data of patients who had an AF-related ischemic stroke and were treated with long-term warfarin therapy in 16 Korean centers. The quality of warfarin therapy was primarily assessed by the time in therapeutic range [TTR; international normalized ratio (INR), 2.0–3.0] and additionally by the proportion of INR values within the therapeutic range. Results The long-term warfarin-treated cohort comprised 1,230 patients. They were aged 70.1±9.7 years (mean±SD), 42.5% were female, and their CHA2DS2-VASc score was 4.75±1.41. The TTR analysis included 33,941 INR measurements for 27,487 months: per patients, 27.6 (SD, 22.4) INR measurements for 22.4 (SD, 12.9) months. The mean TTR of individual patients was 49.1% (95% confidence interval, 47.9–50.3%), and the TTR quartiles were <34.5, 34.5–49.1, 49.1– 64.5%, and >64.5%. None of the 16 centers achieved a mean TTR of >60%. Of all INR measurements, 44.6% were within the therapeutic range, 41.7% were <2.0, and 13.7% were >3.0. Conclusions In Korean ischemic stroke patients who had AF, the quality of warfarin therapy was low and might be inadequate to effectively prevent recurrent stroke or systemic embolism.
참고문헌 (30)
- Jung KH, "Secular trends in ischemic stroke characteristics in a rapidly developed country:results from the Korean Stroke Registry Study (secular trends in Korean stroke)", Circ Cardiovasc Qual Outcomes, 5, pp.327~334 (2012)
- 김범준, "Case Characteristics, Hyperacute Treatment, and Outcome Information from the Clinical Research Center for Stroke-Fifth Division Registry in South Korea", 대한뇌졸중학회지, 17(1), pp.38~53 (2015), 대한뇌졸중학회
- Jones M, "Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with nonvalvar atrial fibrillation: a record linkage study in a large British population", Heart, 91, pp.472~477 (2005)
- Gallagher AM, "Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients", Thromb Haemost, 106, pp.968~977 (2011)
- 김은수, "Estimation of vitamin K intake in Koreans and determination of the primary vitamin K-containing food sources based on the fifth Korean National Health and Nutrition Examination Survey (2010-2011)", Nutrition Research and Practice, 7(6), pp.503~509 (2013), 한국영양학회
- Bae JW, "Allele and genotype frequencies of CYP2C9 in a Korean population", Br J Clin Pharmacol, 60, pp.418~422 (2005)
- Gaikwad T, "VKORC1 and CYP2C9 genotype distribution in Asian countries", Thromb Res, 134, pp.537~544 (2014)
- Wallentin L, "Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial", Lancet, 376, pp.975~983 (2010)
- Singer DE, "Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial", J Am Heart Assoc, 2, pp.e000067~ (2013)
- Wallentin L, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation", Circulation, 127, pp.2166~2176 (2013)
- Shimada YJ, "Effects of regional differences in Asia on efficacy and safety of edoxaban compared with warfarin--insights from the ENGAGE AFTIMI 48 trial", Circ J, 79, pp.2560~2567 (2015)
- 박윤경, "Lack of Association of Clinical Factors (SAMe- TT2R2) with CYP2C9", VKORC1 Genotype and Anticoagulation Control Quality, 2015, pp.17(2), 192~198[DOI]
- Rosendaal FR, "A method to determine the optimal intensity of oral anticoagulant therapy", Thromb Haemost, 69, pp.236~239 (1993)
- Dixon WJ, "Introduction to Statistical Analysis", pp.105~107 (1983), McGraw-Hill
- Thane CW, "Comparative dietary intake and sources of phylloquinone (vitamin K1) among British adults in 1986-7 and 2000-1", Br J Nutr, 96, pp.1105~1115 (2006)
- Fulgoni VL, "Foods, fortificants, and supplements: where do Americans get their nutrients?", J Nutr, 141, pp.1847~1854 (2011)
- Tsuboyama-Kasaoka N, "Dietary intake of nutrients with adequate intake values in the dietary reference intakes for Japanese", J Nutr Sci Vitaminol (Tokyo), 59, pp.584~595 (2013)
- Chiang CE, "Stroke prevention in atrial fibrillation:an Asian perspective", Thromb Haemost, 111, pp.789~797 (2014)
- JCS Joint Working Group, "Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version", Circ J, 74, pp.2479~2500 (2010)
- Yamaguchi T., "Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group", Stroke, 31, pp.817~821 (2000)
- Yasaka M, "Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation", Intern Med, 40, pp.1183~1188 (2001)
- Inoue H, "Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM registry", Circ J, 77, pp.2264~2270 (2013)
- Connolly SJ, "Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range", Circulation, 118, pp.2029~2037 (2008)
- Ansell J, "Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 133(6 Suppl), pp.160S~198S (2008)
- 신홍원, "Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KORean Atrial Fibrillation Investigation", Korean Circulation Journal, 42(2), pp.113~117 (2012), 대한심장학회
- Lip GY, "Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal", Int J Cardiol, 180, pp.246~254 (2015)
- Kasmeridis C, "Cost effectiveness of treatments for stroke prevention in atrial fibrillation:focus on the novel oral anticoagulants", Pharmacoeconomics, 31, pp.971~980 (2013)
- Chang CH, "Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan", Thromb Res, 133, pp.782~789 (2014)
- Nelson WW, "Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation", Am J Cardiol, 112, pp.509~512 (2013)
- Apostolakis S, "Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score", Chest, 144, pp.1555~1563 (2013)